<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611804</url>
  </required_header>
  <id_info>
    <org_study_id>SYM 2015-01</org_study_id>
    <nct_id>NCT02611804</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety profiles of Teva's Diclofenac Sodium Gel, 5% (test
      product) to Solaraze® (diclofenac sodium) Gel, 3% (reference product) to demonstrate the
      clinical equivalence and to show that the efficacy of the 2 active formulations is superior
      to that of vehicle in treating subjects with actinic keratosis (AK) on the face or bald
      scalp.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients with Treatment Success at Visit 4</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">492</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Gel, 3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Sodium Gel, 3%, applied twice daily for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solaraze®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of Test Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of Test Product, Gel, applied twice daily for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium</intervention_name>
    <arm_group_label>Diclofenac Sodium Gel, 3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium</intervention_name>
    <arm_group_label>Solaraze®</arm_group_label>
    <other_name>Solaraze®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle of Test Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent for the study.

          -  At least 18 years of age

          -  Immunocompetent male or nonpregnant and nonlactating female. Each female subject of
             childbearing potential (excluding women who are surgically sterilized or
             postmenopausal for at least 2 years), in addition to having a negative urine pregnancy
             test at Visit 1/Day 1, must be willing to use an acceptable form of birth control
             during the study. For the purpose of this study, the following are considered
             acceptable methods of birth control: oral contraceptives, contraceptive patches,
             contraceptive implant, vaginal contraceptive, double-barrier methods (e.g., condom and
             spermicide), contraceptive injection (Depo-Provera®), intrauterine device IUD
             (Mirena®), Essure®, and abstinence with a documented second acceptable method of birth
             control if the subject becomes sexually active.

          -  Clinical diagnosis of AK, defined as ≥ 5 and ≤ 10 clinically typical, visible,
             discrete, nonhyperkeratotic, nonhypertrophic AK lesions, each at least 4 mm in
             diameter, contained within a 25-cm2 treatment area on either the face or bald scalp,
             but not both face and scalp.

          -  In general good health and free from any clinically significant disease, other than
             AK, that might interfere with the study evaluations.

          -  Willing and able to understand and comply with the requirements of the study, apply
             the study medication as instructed, attend the required visits, comply with therapy
             prohibitions, and be able to complete the study.

        Exclusion Criteria:

          -  Presence of active gastrointestinal ulceration or bleeding.

          -  Presence of severe renal or hepatic impairment.

          -  Presence of atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea,
             squamous cell carcinoma, sunburn, or other possible confounding skin conditions on the
             treatment area of either the face or bald scalp.

          -  Clinically significant systemic disease (immunological deficiencies), unstable medical
             disorder, life-threatening disease, or current malignancies.

          -  Use within 6 months (180 days) prior to randomization of oral isotretinoin.

          -  Use within 6 months (180 days) prior to randomization on the face or bald scalp where
             the designated treatment area is located of 1) chemical peel, 2) dermabrasion, 3)
             laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy.

          -  Use within 6 months (180 days) prior to randomization of systemic cancer chemotherapy
             medications.

          -  Use within 1 month (30 days) prior to randomization on the face of bald scalp where
             the designated treatment are is located of 1) cryodestruction or chemodestruction, 2)
             curettage, 3) photodynamic therapy, 4) surgical excision, 5) topical 5-fluorouracil,
             6) topical corticosteroids, 7) topical diclofenac, 8) topical imiquimod, 9) topical
             retinoids, 10) other treatments for actinic keratosis.

          -  Use within 1 month (30 days) prior to randomization of 1) immunomodulators or
             immunosuppressive therapies, 2) interferon, 3) systemic (oral and injectable)
             corticosteroids, 4) cytotoxic drugs. Intranasal or inhaled corticosteroids are
             acceptable if kept constant throughout the study. Intra-articular injection of
             steroids is acceptable for this study.

          -  Known hypersensitivity or allergies to diclofenac, benzyl alcohol, polyethylene glycol
             monomethyl ether 359, hyaluronate sodium or any component of the study medication (in
             any dosage form).

          -  Previous or current history of allergies to aspirin (ASA) or other NSAIDS.

          -  Females who are pregnant, breastfeeding, intending to become pregnant during the
             study, or who do not agree to use an acceptable form of birth control during the
             study.

          -  Any clinically significant condition or situation other than the condition being
             studied that, in the opinion of the investigator, would interfere with the study
             evaluation or optimal participation in the study.

          -  Use of any investigational drug or investigational device within 1 month (30 days)
             prior to the randomization.

          -  Previous participation in this study.

          -  Current involvement in activities that require excessive or prolonged sun exposure.

          -  Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise
             the subject's ability to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Agave Clinical Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TCR Medical Corporation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermOne of North Carolina</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Dermatology</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC Trials</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Miller, M.D.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education and Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

